HRT Financial’s VanEck Biotech ETF BBH Stock Holding History

HRT Financial’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,510	Closed	-$462K	–	116
2016 Q2	$462K	Sell	4,510 -1,257	-22%	-$134K	0.28%	48
2016 Q1	$597K	Buy	5,767 +3,467	+151%	+$362K	0.62%	25
2015 Q4	$291K	Sell	2,300 -15,054	-87%	-$1.84M	0.35%	36
2015 Q3	$1.98M	Buy	+17,354	New	+$2.3M	1.69%	13

Other funds holding BBH

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

HRT Financial's BBH Position: Q3 2016 in Review

HRT Financial sold out of VanEck Biotech ETF (BBH) in Q3 2016, closing a stake of 4,510 shares — an estimated $462K sold.

HRT Financial first reported a position in BBH in Q3 2015 and held it in 4 quarters. The position peaked at $1.98M in Q3 2015. 79 funds tracked by Wall St. Rank hold BBH as of Q3 2016.

HRT Financial reported no remaining VanEck Biotech ETF position as of Q3 2016 after selling out during the quarter.
HRT Financial sold 4,510 VanEck Biotech ETF shares in Q3 2016, an estimated $462K.
HRT Financial first reported a position in VanEck Biotech ETF in Q3 2015 and held it in 4 quarters.
HRT Financial's VanEck Biotech ETF position peaked at $1.98M in Q3 2015.
79 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2016.

Based on HRT Financial's 13F filing for Q3 2016, filed 9 Nov 2016.